Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ISTH 2022
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
Want to know the key updates in MDS from ASH 2025?
🎧Listen to our podcast: https://ow.ly/ph2q50XJuO9
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)…
🎥 Alexander Perl (@PennMedicine) provides insight into the VICEROY study, a trial evaluating the efficacy, safety, &optimal dosing of the VEN/AZA/GILT triplet regimen in pts with newly diagnosed FLT3-mutated AML:
👉 👈
#AMLsm #Leusm #ASH25 #TrialUpdate…
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, provides insight into the Phase I/II ...
ow.ly
ISTH 2022
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
Want to know the key updates in MDS from ASH 2025?
🎧Listen to our podcast: https://ow.ly/ph2q50XJuO9
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)…
🎥 Alexander Perl (@PennMedicine) provides insight into the VICEROY study, a trial evaluating the efficacy, safety, &optimal dosing of the VEN/AZA/GILT triplet regimen in pts with newly diagnosed FLT3-mutated AML:
👉 👈
#AMLsm #Leusm #ASH25 #TrialUpdate…
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, provides insight into the Phase I/II ...
ow.ly
